Modified iRNA agents
US9290760B2 · kind B2 · utility
90Cited by
0References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2011 |
| Grant date | Mar 22, 2016 |
| Priority date | — |
| Expiry date | Oct 16, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.